Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVX-410 and Citarinostat With and Without Lenalidomide for Smoldering Multiple Myeloma
NCT02886065Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2017
- Primary completion
- Feb 2027
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of pvx-410 and citarinostat in smoldering multiple myeloma (SMM) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Safety And Tolerability Of The PVX-410 Tumor Vaccine Regimen at 2 years. Started Mar 2017; status: active, not recruiting.
02
Drugs
pvx-410citarinostat
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02886065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02886065.